Rufinamide

Rufinamide
	File:Rufinamide.png
Clinical data
ATC code	N03AF03 (WHO) ;
Identifiers
	IUPAC name 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide;
CAS Number	106308-44-5;
PubChem CID	129228;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C10H8F2N4O
Molar mass	238.194

Rufinamide is an anticonvulsant medication.

Used in combination with other medication and therapy to treat Lennox-Gastaut syndrome and various other seizure disorders, Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai.

References

Clinical data
File:Rufinamide.png
ATC code	N03AF03 (WHO)
Identifiers
IUPAC name 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide
CAS Number	106308-44-5
PubChem CID	129228
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₀H₈F₂N₄O
Molar mass	238.194